Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Biomaterials. 2017 Jan 3;121:155–166. doi: 10.1016/j.biomaterials.2017.01.003

Figure 7.

Figure 7

(A) Experimental design for PgP/siRhoA administration timing and outcome assessment over a 4 week time period. Single injection: PgP/siRhoA polyplexes (N/P 30/1, siRhoA 20 μg) were locally injected in the lesion site immediately after SCI injury. Repeat injection: PgP/siRhoA polyplex (N/P 30/1, siRhoA 10 μg/injection) was locally injected in the lesion site immediately after SCI injury and at 1 week post-injury. At 1, 2, and 4 weeks post-injury, spinal cords (0.5 cm-long piece from the center of the injury) were harvested and RhoA knockdown was evaluated by RT-PCR and IHC. (B) RhoA mRNA expression levels evaluated by RT-PCR. Sham animal group and untreated SCI group were used as controls (n=5/group). GAPDH was used as an endogenous control. *P<0.05 compared to Sham, # P<0.05 compared to SCI. (C) Longitudinal sections of SCI lesion sites stained for RhoA (red) and cell nuclei (blue, DAPI) at 4 weeks post-injury. Untreated SCI (top), single-injection (middle), and re-injection (bottom).